Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis

Abstract

Background Randomized controlled trials incorporating validated depression scales have failed to identify an association between interferon beta treatment and depression in MS. This is surprising since interferons used in other clinical contexts are considered capable of causing depression. The negative results in MS could be due inadequate power in the published trials.

Methods In this study, longitudinal data from an IMS Health Canada database called the Therapy Dynamics database were analyzed. The database contains information about prescriptions filled at outpatient pharmacies in Canada, linked at the individual level over time periods as long as 36 months. Antidepressant prescriptions were used as a proxy indicator for depressive disorders. The frequency of antidepressant use was compared in cohorts treated with glatiramer acetate and interferon beta.

Results No differences in the frequency of antidepressant treatment were observed. A large proportion (approximately 40%) in all treatment cohorts were treated with antidepressants at some time over the study interval. The proportions remained comparable after adjustment for age and sex and in a time-to-event analysis of new antidepressant prescriptions. Among patients receiving prescriptions exclusively from Neurologists, the frequency of exposure to antidepressants was much lower (2.4%).

Conclusions This analysis uncovered no evidence that antidepressant treatment occurs more often in people treated with interferon beta than in those treated with glatiramer acetate. These results help to confirm that depression is not associated with interferon beta treatment in MS. Multiple Sclerosis 2008; 14: 406—411. http://msj.sagepub.com

Keywords

interferons interferon-beta depressive disorder antidepressive agents multiple sclerosis

Get full access to this article

View all access options for this article.

References

Klapper JA Interferon beta treatment of multiple sclerosis . Neurology 1994; 44: 188 .

IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-61.

Fukunishi K. , Tanaka H. , Maruyama J. , Takahashi H. , Kitagishi H. , Ueshima T. et al. Burns in a suicide attempt related to psychiatric side effects of interferon . Burns 1998; 24(6): 581-3.

Okanoue T. , Sakamoto S. , Itoh Y. , Minami M. , Yasui K. , Sakamoto M. et al. Side effects of high-dose interferon therapy for chronic hepatis C . J Hepatol 1996; 25: 283-91.

Fattovich G. , Guistina G. , Favarato S. , Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon . J Hepatol 2003; 24: 38-47.

Durelli L. , Bongioanni MR , Ferrero B. , Imperiale D. , Verdun E. , Oggero A. et al. Long term recombinant interferon alpha treatment in MS with special emphasis to side effects . Mult Scler 1996; 1: 366-71.

Miyaoka H. , Otsubo T. , Kamijima K. , Ishii M. , Onuki M. , Mitamura K. Depression from interferon therapy in patients with hepatitis C . Am J Psychiatry 1999; 156(7): 1120 .

Renault PF , Hoofnagle JH , Park Y. , Mullen KD , Peters M. , Jones B. et al. Psychiatric complications of long-term interferon alfa therapy . Arch Intern Med 1987; 147: 1577-80.

Thomas MA , Ibanez HE Interferon alfa-2a in the treatment of subfoveal choroidal neovascularization . Am J Ophthalmol 1993; 115: 563-8.

10.

Merimsky O. , Reider-Groswasser I. , Inbar M. , Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma . Eur J Cancer 1990; 26(5): 596-600.

11.

Mazzaro C. , Lacchin T. , Moretti M. , Tulissi P. , Manazzone O. , Colle R. Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia . Clin Exp Rheumatol 1995; 13 (Suppl 13): S181-S185.

12.

Okereke OI Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma . Psychosomatics 2002 ; 43(3): 237-40.

13.

Adams F. , Quesada JR , Gutterman JU Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer . JAMA 1984; 252: 938-41.

14.

Dieperink E. , Ho SB , Tetrick L. , Thuras P. , Dua K. , Willenbring ML Suicidal ideation during interferonα2b and ribaviron treatment of patients with chronic hepatitis C . Gen Hosp Psychiatr 2004; 26: 237-40.

15.

Bonaccorso S. , Marino V. , Biondi M. , Grimaldi F. , Ippoliti F. , Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus . J Affect Disord 2002; 72: 237-41.

16.

Castera L. , Zigante F. , Bastie A. , Buffet C. , Dhumeaux D. , Hardy P. Incidence of interferon alfainduced depression in patients with chronic hepatitis C . Hepatology 2002; 35(4): 978-9.

17.

Hosoda S. , Takimura H. , Shibayama M. , Kanamura H. , Ikeda K. , Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis . Psychiatr Clin Neurosci 2000; 54: 565-72.

18.

Malaguarnera M. , Di Fazio I. , Restuccia S. , Pistone G. , Ferlito L. , Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha . Neuropsychobiology 1998 ; 37(2): 93-7.

19.

European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multi-centre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-7.

20.

Patten SB , Metz LM Interferon beta-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial . Mult Scler 2001; 7(4): 243-8.

21.

Patten SB , Metz LM Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial . Neurology 2002; 59(5): 744-6.

22.

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996 ; 39(3): 285-94.

23.

Jacobs LD , Beck RY , Simon JH , Kinkel RP , Brownsheidle CM , Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis . N Engl J Med 2000; 343: 898-904.

24.

Patten SB , Francis G. , Metz LM , Lopez-Bresnahan M. , Chang P. , Curtin F. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis . Mult Scler 2005; 11: 175-81.

25.

Borràs C. , Rio J. , Porcel J. , Barrios M. , Tintoré M. , Montalban X. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b . Neurology 1999; 52: 1636-9.

26.

Feinstein A. , O'Connor P. , Feinstein K. Multiple sclerosis, interferon beta-1b and depression A prospective investigation . J Neurol 2002; 249(7): 815-20.

27.

Patten SB , Esposito E. , Carter B. Reasons for antidepressant prescriptions in Canada . Phamacoepidemiol Drug Saf 2007; 16: 746-52.

28.

Porcel J. , Río J. , Sánchez-Betancourt A. , Arévalo MJ , Tintoré M. , Téllez N. et al. Long-term emotional state of multiple sclerosis patients treated with interferon beta . Mult Scler 2006; 12: 802-7.

29.

Zivadinov R. , Zorzon M. , Tommasi MA , Nasuelli D. , Bernardi M. , Monti-Bragadin L. et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a . J Neurol Sci 2003; 216: 113-8.

30.

Simone IL , Ceccarelli A. , Tortorella C. , Bellacosa A. , Pellegrini F. , Plasmati I. et al. Influence of interferon beta treatment on quality of life in multiple sclerosis . Health Qual Life Outcomes 2006; 4: 96 .

31.

Galeazzi GM , Ferrari S. , Giaroli G. , Mackinnon A. , Merelli E. , Motti L. et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy . Neurol Sci 2005 ; 26: 255-62.

32.

Arnett PA , Randolph JJ Longitudinal course of depression symptoms in multiple sclerosis . J Neurol Neurosurg Psychiatr 2006; 77: 606-10.

33.

The Goldman Consensus Conference Participants, National MS Society. The Goldman Consensus Statement on Mood Disorders in Multiple Sclerosis . Mult Scler 2005; 11: 328-37.

34.

Patten SB , Svenson LW , Metz LM Descriptive epidemiology of affective disorders in multiple sclerosis . CNS Spectrums 2005; 10: 365-71.

35.

Patten SB , Metz LM , Reimer MA Biopsychosocial correlates of major depression in a multiple sclerosis population . Mult Scler 2000; 6: 115-20.

36.

Schiffer RB , Wineman NM Antidepressant pharmacotherapy of depression associated with multiple sclerosis . Am J Psychiatr 1990; 147(11): 1493-7.

37.

Mohr DC , Boudewyn AC , Goodkin DE , Bostrom A. , Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis . J Cons Clin Psychol 2001; 69: 942-9.

38.

Benedetti F. , Campori E. , Colombo C. , Smeraldi E. Fluvoxamine treatment of major depression associated with multiple sclerosis . J Neuropsychiatry Clin Neurosci 2004; 16: 364-6.